[Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure]
- PMID: 15577034
[Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure]
Abstract
Hyperparathyroidism, renal osteodystrophy and ectopic calcification, caused by hypocalcemia and hyperphosphatemia, are important complication in renal dysfunction, especially in end stage renal disease. Because it is the reason for reducing the survival rate and quality of life in these patients, it is important to control them from early stage in renal dysfunction. K/DOQI (kidney disease outcomes quality initiative) guideline shows us the recommended practical level and its account. It may be helpful for our daily clinical work.
Similar articles
-
Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.Ther Apher Dial. 2005 Feb;9(1):11-5. doi: 10.1111/j.1774-9987.2005.00215.x. Ther Apher Dial. 2005. PMID: 15828900
-
Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.Kidney Int. 2003 Aug;64(2):441-50. doi: 10.1046/j.1523-1755.2003.00126.x. Kidney Int. 2003. PMID: 12846739
-
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.Nephrol Dial Transplant. 2006 Aug;21(8):2065-8. doi: 10.1093/ndt/gfl289. Epub 2006 Jun 9. Nephrol Dial Transplant. 2006. PMID: 16766546 Review. No abstract available.
-
[Front line of management of hyperphosphatemia in hemodialysis patients].Clin Calcium. 2004 May;14(5):771-7. Clin Calcium. 2004. PMID: 15577041 Review. Japanese.
-
Slowing the progression of vascular calcification in hemodialysis.J Am Soc Nephrol. 2003 Sep;14(9 Suppl 4):S310-4. doi: 10.1097/01.asn.0000081666.10967.05. J Am Soc Nephrol. 2003. PMID: 12939387 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical